Literature DB >> 2824559

Oxidants spontaneously released by alveolar macrophages of cigarette smokers can inactivate the active site of alpha 1-antitrypsin, rendering it ineffective as an inhibitor of neutrophil elastase.

R C Hubbard1, F Ogushi, G A Fells, A M Cantin, S Jallat, M Courtney, R G Crystal.   

Abstract

Current concepts relating to the pathogenesis of emphysema associated with cigarette smoking is that an imbalance exists within the lower respiratory tract between neutrophil elastase and the local anti-neutrophil elastase screen, enabling uninhibited neutrophil elastase to destroy the alveolar structures over time. The possible role of alveolar macrophages in contributing to this imbalance was investigated by evaluating the ability of cigarette smokers' alveolar macrophages to inactivate alpha 1-antitrypsin (alpha 1AT), the major anti-neutrophil elastase of the human lower respiratory tract. In vitro, alveolar macrophages of smokers spontaneously released 2.5-fold more superoxide anion and eightfold more H2O2 than macrophages of nonsmokers (P less than 0.01, both comparisons). Using a model system that reproduced the relative amounts of alveolar macrophages and alpha 1AT found in the epithelial lining fluid of the lower respiratory tract, we observed that smokers' macrophages caused a 60 +/- 5% reduction in the ability of alpha 1AT to inhibit neutrophil elastase. In marked contrast, under the same conditions, nonsmokers' macrophages had no effect upon the anti-neutrophil elastase function of alpha 1AT. Addition of superoxide dismutase, catalase, mannitol, and methionine prevented inactivation of alpha 1AT by smokers' macrophages, implying that the release of oxidants mediated the inactivation of alpha 1AT. In addition, by utilizing a recombinant DNA produced modified form of alpha 1AT containing an active site substitution (met358----val), the inactivation of alpha 1AT by smokers' alveolar macrophages was prevented, suggesting that the smokers' macrophages inactivate alpha 1AT by oxidizing the active site of the alpha 1AT molecule. These results suggest that in cigarette smokers, the alveolar macrophage can modulate the activity of alpha 1AT as an inhibitor of neutrophil elastase and thus play a role in the pathogenesis of emphysema associated with cigarette smoking.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2824559      PMCID: PMC442382          DOI: 10.1172/JCI113204

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  47 in total

1.  The effects in vivo and in vitro of oxidative damage to purified alpha1-antitrypsin and to the enzyme-inhibiting activity of plasma.

Authors:  A B Cohen
Journal:  Am Rev Respir Dis       Date:  1979-06

2.  Possible mechanisms of emphysema in smokers. In vitro suppression of serum elastase-inhibitory capacity by fresh cigarette smoke and its prevention by antioxidants.

Authors:  H Carp; A Janoff
Journal:  Am Rev Respir Dis       Date:  1978-09

3.  Small airways in idiopathic pulmonary fibrosis. Comparison of morphologic and physiologic observations.

Authors:  R G Crystal; J D Fulmer; W C Roberts; E R von Gal
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

4.  Possible mechanisms of emphysema in smokers: cigarette smoke condensate suppresses protease inhibition in vitro.

Authors:  A Janoff; H Carp
Journal:  Am Rev Respir Dis       Date:  1977-07

5.  The oxidative inactivation of human alpha-1-proteinase inhibitor. Further evidence for methionine at the reactive center.

Authors:  D Johnson; J Travis
Journal:  J Biol Chem       Date:  1979-05-25       Impact factor: 5.157

Review 6.  alpha1-antitrypsin deficiency (first of two parts).

Authors:  J O Morse
Journal:  N Engl J Med       Date:  1978-11-09       Impact factor: 91.245

Review 7.  Secretory products of macrophages.

Authors:  C F Nathan
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

Review 8.  Alpha1-antitrypsin and its deficiency.

Authors:  F Kueppers; L F Black
Journal:  Am Rev Respir Dis       Date:  1974-08

9.  Alpha-1-antitrypsin content in the serum, alveolar macrophages, and alveolar lavage fluid of smoking and nonsmoking normal subjects.

Authors:  G N Olsen; J O Harris; J R Castle; R H Waldman; H J Karmgard
Journal:  J Clin Invest       Date:  1975-02       Impact factor: 14.808

10.  Origin, Kinetics, and characteristics of pulmonary macrophages in the normal steady state.

Authors:  A B van oud Alblas; R van Furth
Journal:  J Exp Med       Date:  1979-06-01       Impact factor: 14.307

View more
  29 in total

1.  Increased nitric oxide metabolites in exhaled breath condensate after exposure to tobacco smoke.

Authors:  B Balint; L E Donnelly; T Hanazawa; S A Kharitonov; P J Barnes
Journal:  Thorax       Date:  2001-06       Impact factor: 9.139

Review 2.  Proteinases and oxidants as targets in the treatment of chronic obstructive pulmonary disease.

Authors:  Caroline A Owen
Journal:  Proc Am Thorac Soc       Date:  2005

3.  Molecular multitasking in the airspace: alpha1-antitrypsin takes on thrombin and plasmin.

Authors:  Rubin M Tuder; Irina Petrache
Journal:  Am J Respir Cell Mol Biol       Date:  2007-05-31       Impact factor: 6.914

4.  Oxidant/antioxidant imbalance in smokers and chronic obstructive pulmonary disease.

Authors:  I Rahman; W MacNee
Journal:  Thorax       Date:  1996-04       Impact factor: 9.139

5.  Influence of nicotine on tissue trace element concentrations and tissue antioxidant defense.

Authors:  M A Dubick; C L Keen
Journal:  Biol Trace Elem Res       Date:  1991-11       Impact factor: 3.738

6.  Does the oxidation of methionine in thrombomodulin contribute to the hypercoaguable state of smokers and diabetics?

Authors:  Wesley E Stites; Jeffrey W Froude
Journal:  Med Hypotheses       Date:  2006-10-24       Impact factor: 1.538

7.  Strategies for aerosol therapy of alpha 1-antitrypsin deficiency by the aerosol route.

Authors:  R C Hubbard; R G Crystal
Journal:  Lung       Date:  1990       Impact factor: 2.584

8.  α₁-Antitrypsin modulates lung endothelial cell inflammatory responses to TNF-α.

Authors:  Angelia D Lockett; Samuel Kimani; Godfrey Ddungu; Sabine Wrenger; Rubin M Tuder; Sabina M Janciauskiene; Irina Petrache
Journal:  Am J Respir Cell Mol Biol       Date:  2013-07       Impact factor: 6.914

Review 9.  alpha1-Antitrypsin deficiency . 6: new and emerging treatments for alpha1-antitrypsin deficiency.

Authors:  R A Sandhaus
Journal:  Thorax       Date:  2004-10       Impact factor: 9.139

Review 10.  Targeted treatment in COPD: a multi-system approach for a multi-system disease.

Authors:  David Anderson; William Macnee
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.